Scarica l'app Stockscreener
3.20
3.32%
-0.11
Dopo l'orario di chiusura:
3.19
-0.01
-0.31%
Precedente Chiudi:
$3.31
Aprire:
$3.27
Volume 24 ore:
67,618
Relative Volume:
0.65
Capitalizzazione di mercato:
$7.88M
Reddito:
$75,700
Utile/perdita netta:
$-7.23M
Rapporto P/E:
-0.186
EPS:
-17.2081
Flusso di cassa netto:
$-7.37M
1 W Prestazione:
-5.04%
1M Prestazione:
-10.36%
6M Prestazione:
-57.33%
1 anno Prestazione:
-55.24%
Intervallo 1D:
$3.20
$3.30
Intervallo di 1 settimana:
$3.20
$3.46
Portata 52W:
$2.3401
$12.03
Aclarion Inc Stock (ACON) Company Profile
Nome
Aclarion Inc
Settore
Industria
Telefono
833 275 2266
Indirizzo
8181 ARISTA PLACE, BROOMFIELD
Compare ACON vs VEEV, BTSG, TEM, HQY, DOCS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
3.20 | 8.15M | 75,700 | -7.23M | -7.37M | -17.21 |
VEEV
Veeva Systems Inc
|
171.19 | 27.80B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
51.44 | 10.38B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
54.07 | 10.01B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
82.63 | 6.94B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
25.77 | 4.60B | 637.78M | 239.40M | 307.21M | 1.1909 |
Aclarion Inc Borsa (ACON) Ultime notizie
Aclarion establishes second trial agreement with Weill Cornell By Investing.com - Investing.com Canada
Aclarion announces second commercial agreement with Weill Cornell Medicine - marketscreener.com
Weill Cornell adds Aclarion scan to 2-year spine surgery trial - Stock Titan
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine - The Manila Times
Aclarion announces $2.5M stock repurchase plan - MSN
Aclarion reports cash runway to ops into late 2027 - BizWest
Aclarion Reports 196% Annual Scan Volume Growth in Q1 2026, Fueled by Accelerating Clinical Adoption of Nociscan - MEXC Exchange
Aclarion reports 196% jump in Nociscan scan volumes in Q1 - Investing.com UK
Aclarion reports 196% jump in Nociscan scan volumes in Q1 By Investing.com - Investing.com Australia
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption - The Manila Times
Back-pain scan use rose 196% as Aclarion funds operations into 2027 - Stock Titan
Aclarion names Daniel Keefe as commercial director for Western US - Medical Buyer
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued ... - Bluefield Daily Telegraph
Aclarion, Inc. Appoints Daniel Keefe as Commercial Director, Western U.S - marketscreener.com
Aclarion (NASDAQ: ACON) expands 2022 equity plan in 2026 shareholder proxy - Stock Titan
Aclarion authorizes $2.5 million share buyback program By Investing.com - Investing.com India
Aclarion Launches $2.5 Million Share Repurchase Program - The Globe and Mail
Aclarion Announces $2.5 Million Stock Repurchase Plan - Ortho Spine News
Aclarion, Inc. announces an Equity Buyback for $2.5 million worth of its shares. - marketscreener.com
Aclarion authorizes $2.5 million share buyback program - Investing.com
Aclarion authorizes $2.5M share repurchase plan to deploy cash and support Nociscan growth - TradingView
Aclarion (NASDAQ: ACON) launches $2.5M share buyback plan - Stock Titan
With $19M cash, Aclarion plans buybacks while funding Nociscan - Stock Titan
Aclarion, Inc. authorizes a Buyback Plan. - marketscreener.com
Aclarion (ACON) Stock Insider Buying (Eye on Rally) 2026-04-20Community Watchlist - Xã Vĩnh Công
Aclarion receives patent for AI-based pain evaluation platform By Investing.com - Investing.com India
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain - The Manila Times
Aclarion receives patent for AI-based pain evaluation platform - Investing.com
Aclarion, Inc. Secures U.S. Patent for AI-Enhanced Machine Learning Platform in Chronic Low Back Pain Diagnosis - Quiver Quantitative
New Aclarion patent targets faster, more consistent chronic back-pain scans - Stock Titan
Aclarion (ACON) Stock Conversion (Momentum Building) 2026-04-15Long Term Investing - Xã Vĩnh Công
Aclarion's AI Platform Nociscan Wins Pinnacle Award, Validating Approach to Chronic Low Back Pain Diagnosis - citybuzz -
Aclarion Receives Pinnacle Award for AI Innovation - The Manila Times
AI tool for chronic back pain earns Aclarion a second health tech award - Stock Titan
Aclarion (ACON) price target decreased by 69.57% to 7.14 - MSN
Take Profit: Will Opendoor Technologies Inc outperform the market in YEAR2026 Trading Recap & Verified Swing Trading Watchlist - baoquankhu1.vn
Will Aclarion (ACON) Stock Go Higher | Price at $3.80, Up 6.44%Seasonal Patterns - Cổng thông tin điện tử tỉnh Lào Cai
Aclarion Announces Agreement with Weill Cornell Medicine - Bitget
Aclarion establishes agreement with Weill Cornell Medicine By Investing.com - Investing.com Australia
Aclarion Partners with Weill Cornell Medicine to Expand Nociscan Use in Spine Pain Research - citybuzz -
Aclarion establishes agreement with Weill Cornell Medicine - Investing.com
Aclarion Inc Azioni (ACON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.66%
1.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):